Sooma tDCS™ is a class IIa medical device CE approved for treatment of Major Depressive Disorder, Fibromyalgia, and Neuropathic pain. It is an effective and easy-to-use solution for professionals, designed for routine clinical use in co-operation with leading psychiatrists and neurophysiologists.
The treatment is gentle and very well tolerated. It can be used as an alternative to or in combination with psychotherapy, pharmaceuticals, and other neuromodulation treatments.
Sooma tDCS™ is an optimal tool for outcome studies. It supports double-blind condition and can be configured for multiple study protocols. Further, it ensures that every member of the study team perform stimulation in the same way. Contact us to learn more about research co-operation. Please note that research use is investigational and may require ethical committee approval.
For a detailed product overview, see our brochure and our white paper.